TRISTEL PLC

Regulatory Filings • Aug 21, 2020

National Storage Mechanism | Additional information

RNS Number : 7479W

Tristel PLC

21 August 2020

Tristel plc

("Tristel" or the "Company")

Tristel's Duo for Ultrasound approved in India

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that its Duo high-level disinfectants, branded Duo ULT, Duo OPH and Duo EVE, have been approved for the decontamination of semi-critical medical devices by India's Medical Device & Diagnostics Division, Central Drugs Standard Control Organisation (CDSCO).

Duo ULT is intended for use on invasive ultrasound probes; Duo OPH is intended for use on ophthalmic instruments; and Duo EVE is intended for use on Mobile ODT's hand-held EVA colposcope and associated instruments used in gynaecological procedures.

In 2019 the Company received regulatory approvals from the CDSCO for Stella, which is an instrument soaking system for urological instruments, and Rinse Assure which is used with endoscope washer-disinfectors. Tristel incorporated Tristel India Private Limited during its 2018 financial year.

Duo is a hand-held dispenser which applies the Company's powerful chlorine dioxide chemistry as a foam to the surface of medical devices. Tristel Duo is widely used throughout Europe, the Middle East and the Asia-Pacific region and the Company is seeking approval for Duo ULT from the United States Food and Drug Administration. Worldwide sales of all Duo branded products for medical device disinfection were £3.9m in the 2020 financial year, an increase of 56% on the prior year.

Paul Swinney, CEO of Tristel commented: "Every regulatory approval we achieve represents an important milestone in our progress, and this Indian approval for the use of our high-level disinfectants on invasive medical devices is no exception. The three Duo products provide Indian hospitals with an affordable and easy-to-use high-level disinfection method for medical devices used in ultrasound, ophthalmology, and gynaecology. Infection prevention experts within India acknowledge the need for disinfection technologies that will enable hospitals to raise their decontamination standards. Combining these latest approvals with those previously gained gives us a broad product offering for the Indian market.   

"We can now press on with developing our commercial plan for India. We have initiated discussions with various potential partners for distribution of the products."

For further information please contact:       

## Tristel plc	Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director
Walbrook PR Ltd	Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303
finnCap	Tel: 020 7220 0500
Geoff Nash/ Giles Rolls (Corporate Finance)
Alice Lane (ECM)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAKZGZRFGRGGZM